[Explanation] Wearing a white coat and conducting genetic sampling tests in the laboratory is Shi Mingyao, a young entrepreneur from Hong Kong.

Born in a housing estate, he graduated from the Chinese University of Hong Kong with a major in Biomedical Engineering.

In 2015, in order to be able to devote himself to biotechnology research, he founded a biotechnology company of his own.

He admitted that he has always hoped to apply the theory he has learned to practical life to provide more help to patients.

  [Concurrent] Shi Mingyao, CEO of Shanmi Co., Ltd.

  In the beginning, I didn't plan to do (start-up), that is, in my life (planning), from middle school to university, there is no concept that I want to be an entrepreneur, I want to be a start-up.

To put it in reverse, because I really like biotechnology, I felt that biotechnology is actually a human problem. I think it is a very meaningful thing to spend your whole life trying to solve human problems. It is mainly based on I really wanted to put what I learned and the accumulated experience into clinical application for some people, so I ran out (starting up).

  [Explanation] After years of hard work, the team led by Shi Mingyao has developed key technologies such as blood genetic testing that can prevent cancer.

Looking back on his entrepreneurial journey, Shi Mingyao said that the biggest difficulty he had faced was the incomprehension of his family and the doubts of his friends.

  [Concurrent] Shi Mingyao, CEO of Shanmi Co., Ltd.

  In 2006, I started (studying) my biomedical engineering. In fact, most of them were studying business and hotel management at that time, so my mother said to me at that time, "Are you sure you want to take such a special path?" Frankly speaking, my mother has always said this concept. My mother may not understand what I do all the time, so my first difficulty is that when you do something innovative, the biggest pressure is you People around you don't understand what you're doing, and that can put a lot of pressure on you.

  [Explanation] As early as 2019, the State Council promulgated the "Guangdong-Hong Kong-Macao Greater Bay Area Development Plan", proposing that medical data and blood and other biological samples required for scientific research cooperation projects need to cross-border in the Greater Bay Area. Optimal management for laboratory use.

This allowed Shi Mingyao to see new opportunities.

  [Concurrent] Shi Mingyao, CEO of Shanmi Co., Ltd.

  But frankly speaking, medical data is more sensitive now, because it is more sensitive to each country, but this sensitivity will cause a problem, that is, we cannot integrate the data of the whole world, and then find some in the database of the whole world. New discoveries, let it contribute to mankind.

This was the problem before, but the emergence of the Greater Bay Area actually gave hope to solve this problem, because in the program of the Greater Bay Area, the Hetao (area) is a pilot project. First, let (medical) data follow (medical) ) The samples are freely in and out (within a limited range), so for us, it is a great opportunity for Hong Kong. In the future, the Hetao area of ​​the Greater Bay Area will be our Hong Kong's leading role in biotechnology One of the best proving grounds.

  [Explanation] Under the epidemic, the safety and health of Hong Kong citizens has been impacted. In addition to donating alcohol, disinfectant, masks and other epidemic prevention items to citizens in surrounding areas, Shi Mingyao and his team also helped the government to track the source of the disease and inject positive energy into epidemic prevention and control. energy and make positive contributions to the stable development of Hong Kong.

  [Concurrent] Shi Mingyao, CEO of Shanmi Co., Ltd.

  In fact, we are also doing some research and development related to COVID-19 (new crown pneumonia). For example, it is the easiest at the beginning. Everyone is doing nucleic acid testing, but the question is how to trace the source of that (virus) after it is done?

In fact, we have a technology, which I mentioned just now is NGS (high-throughput sequencing technology), and the government is also using (our) technology to trace the source of this (virus).

  Reporter Luo Siyu reports from Hong Kong

Responsible editor: [Fang Jialiang]